GANX - CIK 0001819411
The table below shows Gain Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.54M | $8.81M | $6.69M | $9.07M | $12.05M | $16.94M |
| Short-term investments | - | - | - | - | $5.00M | $5.00M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $18.22M |
| $10.52M |
| $9.31M |
| $11.15M |
| $13.74M |
| $18.54M |
| Property, plant & equipment | $54.44K | $85.57K | $96.19K | $97.51K | $119.61K | $123.93K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $18.74M | $10.97M | $9.83M | $11.62M | $14.37M | $19.20M |
| Accounts payable | $1.52M | $1.58M | $2.71M | $2.15M | $1.10M | $2.05M |
| Total current liabilities | $3.89M | $4.17M | $5.20M | $5.03M | $4.59M | $6.52M |
| Long-term debt | $273.26K | $298.80K | $325.36K | $314.48K | $376.13K | $375.35K |
| Total liabilities | $4.73M | $5.06M | $6.14M | $5.84M | $5.46M | $7.41M |
| Retained earnings | -$101.36M | -$81.19M | -$81.19M | -$81.19M | -$60.78M | -$60.78M |
| Total equity | $14.01M | $5.91M | $3.70M | $5.78M | $8.91M | $11.78M |